San Diego, California--(Newsfile Corp. - January 27, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reported that its Phase 2 clinical trial protocol has received study level approval from a central institutional review board ("IRB"). The Phase 2 study is a planned evaluation of SBI-100... Read more
TORONTO and GLIL YAM, Israel, Jan. 27, 2023 /CNW/ - IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company announces that it has engaged certain eligible finders (each a "Finder"), in connection with its previously announced private placement offering of units of the Company (each, a "Unit") pursuant to the listed issuer financing exemption under Part 5A of... Read more
Reports Quarterly Revenue of US$7.8 Million & Highlights Recent Developments LAS VEGAS and VANCOUVER, BC, Jan. 25, 2023 /CNW/ - Body and Mind Inc. (CSE: BAMM) (OTCQB: BMMJ) (the "Company" or "BaM"), a multi-state operations-focused cannabis company, is pleased to announce financial results for the first quarter of fiscal year 2023 ended October 31, 2022 and to provide shareholders with an operational... Read more
Hunt Valley, MD, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO), proudly celebrates a first-in-human Phase I clinical study for Skye Bioscience, Inc.’s (SKYE: OTCQB) proprietary, synthetic cannabinoid derivative, SBI-100 Ophthalmic Emulsion (OE), which has been designed to advance a new mechanism of action with potential as a... Read more
Following the Government of Colombia's decision on insurance coverage for medical cannabis, Khiron has begun dispensing medical cannabis to its patient base under the new mandate. TORONTO, Jan. 19, 2023 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), announces that it has begun dispensing medical cannabis to patients in its wholly owned ZereniaTM... Read more
Reports Annual Revenue of US$31.6 Million & Highlights Recent Developments LAS VEGAS and VANCOUVER, BC, Jan. 18, 2023 /CNW/ - Body and Mind Inc. (CSE: BAMM) (OTCQB: BMMJ) (the "Company" or "BaM"), a multi-state operations-focused cannabis company, is pleased to announce financial results for the fiscal year ended July 31, 2022 and to provide shareholders with an operational update. All financial information is... Read more
Smaller bottle allows for consumers flexibility at a more affordable price SAN DIEGO, Jan. 18, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced the launch of their popular +PlusCBD™ Reserve Collection... Read more
The Company has already secured approvals from Ethics Committee and Israeli Ministry of Health for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 18, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders... Read more
Zerenia™ Clinics UK, wholly owned by Khiron, succeeds at having the NHS reimbursing both the cost of cannabis-based treatment and clinic fees to its first patient Khiron trains doctors and nurses at an NHS- funded hospital on how to integrate CBMPs (cannabis-based products for medicinal use in humans) to treatment options Khiron will be presenting its new real-world clinical evidence at the upcoming... Read more
Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the pathogenesis of Fragile X syndrome (FXS) Cannabidiol may help restore the function of the ECS in FXS patients according to review of data Consistent with the proposed mechanisms of action of cannabidiol in FXS, Zygel™ showed a significant reduction in behavioral symptoms,... Read more
Achieved $29.2 Million of Operating Cash Flow and $25.4 Million of Free Cash Flow 15th Consecutive Quarter of Positive Adjusted EBITDA Maintains Leading Market Share Position in Recreational Cannabis in Canada and Medical Cannabis Across Europe Net Revenue of $144.1 Million, On a Constant Currency Basis $157.6 million EPS of -$0.11 and Adjusted EPS of -$0.06 Strategy in Place to Build the World’s Leading and... Read more
Vancouver, British Columbia--(Newsfile Corp. - January 9, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has entered into a license agreement with its subsidiary PreveCeutical (Australia) Pty Ltd. (the "Subsidiary" or "PAPL") for the exclusive rights to the Sol-Gel intellectual property and technology for the... Read more
New TnT strains expand HEXO's top-selling portfolio and are crafted to create a fulsome sensory experience for the consumer HEXO Corp. (TSX: HEXO; NASDAQ: HEXO) ("HEXO" or the “Company”), a leading producer of high-quality cannabis products, is pleased to announce the launch of its new TnT Cannabis strains under the Redecan and Original Stash Brands labels across Canada. The new strains further expand HEXO’s... Read more
Ethics Committee and Israeli Ministry of Health approvals already received for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 09, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has signed... Read more
On December 27, 2022, Zerenia (Khiron´s wholly owned medical cannabis clinic network) signed a contract with CAPITAL SALUD EPS, Colombia´s largest public insurance company, under which Zerenia will provide medical cannabis services and products to its patient population, directly reimbursed by CAPITAL SALUD EPS. CAPITAL SALUD EPS is owned by the City of Bogota and insures more than 1.2 million people in and... Read more
KELOWNA, BC / ACCESSWIRE / December 29, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce its continued accumulation of international patent recognition with the receipt of its first granted patent in Canada, which is its 28th granted patent worldwide. Canadian Patent #3,093,414 is the first granted patent... Read more
VANCOUVER, BC / ACCESSWIRE / December 28, 2022 / 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF) (OTCQB:TGIFF), a Nevada-focused cannabis consumer packaged goods company, is pleased to announce its first quarter financial results ("Q1 2023") For the three months ended October 31, 2022 and 2021 ("Fiscal 2023"). All amounts expressed are in Canadian dollars. The Company owns 91% of Alternative... Read more
Second Clarifax received from Health Canada. MONTREAL, Dec. 22, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with another regulatory update on the REDUVO™ New Drug Submission (NDS). The last update was provided on November 18, 2022. On December 21, 2022, the Company... Read more
Two global leaders in the medical wellness cannabis industry expected to combine complementary strengths of diversified revenue in multiple markets and channels to create a pro-forma Combined Company with over $50M in annualized revenue, based on Q3 2022.(1)(2)(3)(4) Pro-forma Combined Company is expected to have positive EBITDA(5) synergies of between $7M to $9M on an annualized basis within 12 months closing... Read more
MIAMI, Dec. 22, 2022 /CNW/ - Cansortium Inc. (CSE: TIUM.U) (OTCQX: CNTMF) ("Cansortium" or the "Company"), a vertically-integrated cannabis company operating under the Fluent™ brand, announces that, pursuant to a third amendment dated December 21, 2022 (the "Third Amendment") to an existing agreement (as amended, the "Smith Transaction Agreement") among the Company and certain of its affiliates and William Smith, a... Read more
Phase 2 clinical trial planned to start in H1 2023 San Diego, California--(Newsfile Corp. - December 20, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, today announced that the U.S. Food and Drug Administration ("FDA") has given the okay to proceed for the Investigational New Drug ("IND")... Read more
TORONTO, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today announced the launch of a new limited edition, premium craft flower series by lifestyle brand, RIFF. The brand’s new series is designed to introduce two new collections of craft flower featuring a rotation of limited... Read more
San Diego, California--(Newsfile Corp. - December 16, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, has completed dosing of SBI-100 Ophthalmic Emulsion ("OE") in the first cohort of healthy participants in the single ascending dose ("SAD") part of its Phase 1 study... Read more
ST PETER PORT, GUERNSEY / ACCESSWIRE / December 16, 2022 / Goodbody Health Limited (AQSE:GDBY)(OTCQB:GDBYF) ("Goodbody" or the "Company"), today announces that that it has agreed to sell the Polish CBD related elements of its operations to Voyager Life PLC ("Voyager") in return for a consideration of £1.5m, comprising £0.5m cash and £1.0m convertible loan notes ("CLNs"). The divestment comprises the share sale of... Read more
Strategic realignment demonstrates significant results across the business, including quarter over quarter improvements to Adjusted EBITDA and increased gross margin before adjustments HEXO has signed new cultivation agreements and purged unprofitable sales Redecan brand achieved record sales, prompting 300% increase in production GATINEAU, Quebec, Dec. 15, 2022 (GLOBE NEWSWIRE) -- HEXO Corp. (TSX: HEXO;... Read more
LAS VEGAS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is addressing the growing need for anxiety and depression medications through the development of novel, kava-inspired formulations, which are mood altering but non-hallucinogenic. Recently, Gb Sciences received positive preclinical results supporting the efficacy... Read more
LOS ANGELES, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of the assets of Clare Clinic, Inc., d/b/a Florida Mind Health Center. The Company entered into an acquisition agreement (the “Agreement”) dated October 30, 2022 with Clare Clinic, Inc., d/b/a Florida Mind Health Center, which serves clients out of... Read more
The non- clinical study was conducted at The Chaim Sheba Medical Center in Israel Tel-Aviv, Dec. 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced positive results from its study of SCI-210 on Status Epilepticus ("SE"),... Read more
TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, announced today the launch of Peppermint Phatty 510 vape, the newest addition to the Good Supply vape lineup. Just in time for the holidays, Peppermint Phatty is packed with peppermint and vanilla aromas and topped off with a... Read more
Represents PharmaCielo's first shipment to Africa. Morocco is pioneering the commercialization of cannabinoid products on the African continent and will be a growing market. The Company also announced that it has agreed to issue shares in settlement of certain interest payments and debt. TORONTO, Canada and RIONEGRO, Colombia, Dec. 5, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the... Read more
New dispensary expands patient access to medical cannabis; grand opening specials available TALLAHASSEE, Fla., Dec. 2, 2022 /CNW/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the opening of a new medical dispensary in Hobe Sound, Florida. Located at 10835 SE Federal Hwy., the doors will open... Read more
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce that it has signed a consulting agreement with Benitz Consulting LLC ("Benitz Consulting") to assist the Company's... Read more
In Europe, revenues increased by 141% year-over-year, driven by revenues in the United Kingdom, where the Corporation is now increasing its existing product portfolio, and the specialized cannabis clinic Zerenia™ Clinics UK celebrates its first anniversary. Overall revenues for Q3 2022 decreased 24% driven primarily by a reduction of medical cannabis sales in Colombia, due to an interruption in insurance-covered... Read more
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report its financial results for the three and nine months ended September 30, 2022. "We delivered encouraging results in the third quarter, with revenue growth... Read more
Study finds patients with Fragile X who have a highly methylated FMR1 gene that were treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with placebo Topline results from follow-on RECONNECT confirmatory pivotal Phase 3 trial of Zygel in patients with a completely methylated FMR1 gene expected in second half 2023 DEVON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) --... Read more
MELBOURNE, Australia, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing medicinal cannabinoid and psychedelic therapies for unmet medical needs, is delighted to announce that it has engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific (‘Eurofins’) to... Read more
Successful completion of TSX listing review Expansion of adult-use portfolio into key fifth province 5 provinces now selling Aleafia’s adult-use products TORONTO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Further to its previous announcements, Aleafia Health Inc. (TSX: AH, OTCQB: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce that it has completed the TSX delisting review and confirms that the... Read more
SAN DIEGO, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today its financial results for the quarter ending September 30, 2022, and provided an overview of recent... Read more
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a PCT (Patent Cooperation Treaty) application number PCT/IB2022/06117 on November 18, 2022, entitled "Peptides and Uses Thereof", with the aim of seeking protection for certain peptides comprising D-amino acids and their use in methods of treating brain cancer. This patent... Read more
PCG Digital -- Lexaria Bioscience (NASDAQ: LEXX) is investigating the potential therapeutic utility of its proprietary DehydraTECHTM-CBD against dementia and diabetes, two of the world's biggest public health crises. Lexaria Bioscience The global dementia drug market is projected to reach $32.3 billion by 2030 diabetes and the diabetes drug market is expected to reach $82.92 billion by 2027. Lexaria recently... Read more
COPYRIGHT ©2022 GREEN STOCK NEWS